CIPLA
Back to Income Statement
|
CIPLA Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹25,774 Cr | ₹22,753 Cr | ₹21,763 Cr | ₹19,160 Cr | ₹17,132 Cr |
What is the latest Revenue of CIPLA ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹25,774 Cr |
| Mar2024 | ₹22,753 Cr |
| Mar2023 | ₹21,763 Cr |
| Mar2022 | ₹19,160 Cr |
| Mar2021 | ₹17,132 Cr |
How is Revenue of CIPLA Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹25,774 Cr | 13.28 | |
| Mar2024 | ₹22,753 Cr | 4.55 | |
| Mar2023 | ₹21,763 Cr | 13.59 | |
| Mar2022 | ₹19,160 Cr | 11.84 | |
| Mar2021 | ₹17,132 Cr | - | |
Compare Revenue of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹114,562.2 Cr | 1.2% | 7.7% | -3.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹442,677.0 Cr | -2.4% | 6.4% | 7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹180,458.0 Cr | -0.9% | 5% | 3.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹153,685.0 Cr | 1.6% | 7.6% | 38.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹110,095.0 Cr | 0.1% | -1.2% | 8.7% | Stock Analytics | |
| MANKIND PHARMA | ₹99,957.1 Cr | -3.7% | 6.8% | -0.8% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 1.2% |
7.7% |
-3.4% |
| SENSEX | 0.7% |
-1% |
-7% |
You may also like the below Video Courses